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Abstract
Background—Combination antiretroviral therapy (ART) for HIV-1 infected individuals 
prevents sexual transmission if viral load is suppressed.
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Methods—Participants were HIV-1 infected partners randomized to early ART (CD4 350-550) 
in HPTN052 (n=886, median follow-up = 2.1 years), a clinical trial of early ART to prevent sexual 
transmission of HIV-1 in serodiscordant couples at 13 sites in 9 countries. Adherence was 
assessed via pill-count (dichotomized at <95%) and via self-report items. Predictors of adherence 
were mental health and general health perceptions, substance use, binge drinking, social support, 
sexual behaviors, and demographics. Viral suppression was defined as HIV plasma viral load 
<400 copies/ml. Adherence counseling and couples counseling about safer sex was provided. 
Logistic and linear regression models using generalized estimating equation for repeated 
measurements were employed.
Findings—Via pill-count, 82% of participants were adherent at 1 month and 83.3% at 1 year. 
Mental health was the only psychosocial variable associated with adherence (pill-count OR=1.05: 
95% CI: 1.00 – 1.11; self-report parameter estimate (b)=0.02, 95% CI: 0.01 –0.04), though 
regional differences emerged. Pill-count (OR=1.19, 95% CI: 1.10-1.30) and self-report (OR=1.42, 
95% CI: 1.14-1.77) adherence were associated with viral suppression.
Interpretation—While adherence was high among individuals in stable relationships taking 
ART for prevention, mental health and adherence co-varied. Assessing and intervening on mental 
health in the context of promoting adherence to ART as prevention should be explored. Adherence 
and couples counseling, feedback about viral suppression, and/or altruism may also help explain 
the magnitude of adherence observed.
INTRODUCTION
HPTN 052 is a Phase III, randomized, multicenter study in 1763 HIV-1 serodiscordant 
couples in 9 countries where the HIV-1 infected partner was randomized to early or delayed 
ART. The trial demonstrated that ART prevented HIV-1 transmission.1 These results were 
consistent with observational trials.2–4
However, the ability of ART to suppress viral replication is entirely dependent on adherence 
to the medications. Low social support, depression, substance use, side effects, lack of 
counseling, and socio-economic factors have been predictive of poor adherence to ART in 
diverse global settings.5–8 Virtually all earlier studies have examined adherence to ART in 
individuals who were taking ART because it was indicated for more advanced HIV-1 
disease, rather than to prevent transmission to a sexual partner. The present analysis from 
HPTN 052 among those who were randomized to early ART allowed us to evaluate 
predictors of adherence to medication in HIV-1 infected study subjects offered treatment 
directed toward HIV prevention.
METHODS
Details of the HPTN 052 study design can be found both on clinicaltrials.gov NCT00074581 
and in the primary outcome papers.1,9 Participants were enrolled from 13 sites in 9 countries 
(Botswana; Kenya; Malawi; South Africa; Zimbabwe; Brazil; India; Thailand; and United 
States). The study enrolled HIV-1 serodiscordant couples (one partner is infected with 
HIV-1 and the other is not), where the HIV-1 infected partner had a CD4 cell count of 
350-550 cells/mm. Couples had to have been in a stable relationship for at least 3 months, 
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reported 3 or more episodes of vaginal or anal intercourse during the past 3 months, and 
willing to disclose their HIV-1 status to their partner. The study was unblinded. The partner 
infected with HIV-1 was randomized to early or delayed ART. Local Institutional Review 
Boards or Ethics Committees approved the study at each site.
For the present analysis, data were used only from participants randomized to the early 
treatment arm. Accordingly, all participants in the following analyses initiated ART upon 
study enrollment, and all data were from visits after the enrollment visit (following ART 
treatment initiation) through the time when the results of the primary outcome was 
publically released. The median follow up for the present analysis was 2.1 years.
When the study began in 2005, visits were monthly, and beginning in mid-2008 they 
transitioned to quarterly. Adherence and psychosocial data were recorded at each visit. 
Participants were provided regular adherence counseling using an adapted version of the 
Life-Steps intervention10,11 as a base (see http://www.hptn.org/web%20documents/hptn052/
hptn052adherencecounseling.pdf for the initial training material), and regular counseling on 
HIV risk reduction. The Life Steps adherence counseling included a medical provider 
portion, which provided education about ART medications and adherence, and a counselor 
portion, which provided assistance to participants in devising a plan and a back-up plan for 
potential impediments to adherence (e.g., creation of a daily medication schedule, 
developing reminder strategies, handling slips, discussion of involving social supports), 
following a cognitive-behavioral / problem-solving approach. See the on-line Appendix for 
the checklists used by counselors and medical providers. Study drugs included a 
combination of lamivudine and zidovudine (Combivir), efavirenz, atazanavir, nevirapine, 
tenofovir, lamivudine, zidovudine, didanosine, stavudine, a combination of lopinavir and 
ritonavir (Kaletra and Aluvia), ritonavir, and a combination of emtricitabine and tenofovir 
(Truvada). A pre-specified combination of these drugs was provided to participants at each 
visit. For participants with virologic failure, specified second-line treatment regimens were 
provided.
Measures
At every visit, participants completed an interviewer-administered adherence questionnaire 
in the local language (translated, back translated, discrepancies reviewed and corrected) and 
pill counts were conducted, which yielded a non-adherence self-report score and a non-
adherent pill-count categorization respectively. The additional psychosocial variables were 
collected at every quarterly visit. At all sites, self-report measures were translated and back-
translated to maximize accuracy. These measures are described below.
Adherence questionnaire—The adherence questionnaire began with a grid whereby 
each study drug was listed with the number of doses prescribed per day filled in by study 
staff. Participants would answer the number or prescribed doses missed for “yesterday”, “2 
days ago”, “the past two weeks” and “the past 30 days”. We followed the methodology of 
Reynolds et al.12 to calculate the adherence ratios for yesterday, 2 days ago, in the past two 
weeks and in the past 30 days as 1-(number of doses missed for the time period divided by 
the number of doses prescribed). They were then asked a series of questions including when 
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they last missed medications (within past week, 1-2 weeks ago, 2-4 weeks ago, or never, and 
skipped/not applicable), how many days they had missed taking all of their doses during the 
past four days (none, one day, two days, three days, four days), and whether they missed any 
medications over the past weekend (yes/no for Saturday or Sunday). The 7 self-report 
questions (4 adherence ratios and the 3 questions above) were subjected to a principal 
component analysis (PCA) to construct a non-adherence factor approximating a continuous 
latent variable. This PCA was conducted separately for each study visit. Inspection of the 
scree plot13 and the result that only the first PC had an eigenvalue greater than 114 lead us to 
retain one principal component as the self-report PCA adherence score. This procedure of 
using the available self-report questions to create a self-report continuous PC, and maximize 
variability has been successfully employed in similar studies12,15 and the resulting variable 
was relatively uni-modally distributed..
Additionally, participants were asked about potential reasons for non-adherence. This 
involved a checklist for “never,” “rarely,” “sometimes,” and “often,” and had 24 potential 
reasons for non-adherence such as “forgot,” “side effects,” “transportation problems getting 
to the clinic,” and “lost pills,” which were generated from the study sites and using items 
from prior AIDS Clinical Trials Group (ACTG) trials.16 The most frequently reported 
reasons are described in the study results.
Pill Count—At each study visit, study nurses dispensed pills expected for the following 
quarter and participants were instructed to bring any remaining pills to the clinic at the next 
visit for a pill count. The adherence percentage was calculated for each participant as 
dividing the total number of pills taken by the total number of pills that should have been 
taken since ART initiation. A binary adherence variable (<95% vs. 95-100%) was then 
created.
Psychosocial Interview—The psychosocial interview included a modified version17 of 
the ACTG SF-2118 quality of life questionnaire. To simplify the analyses, and based on 
prior adherence research, only the general health perceptions and mental health subscales 
were included. We also included one question about general satisfaction with social 
support,16,17,19 which asked about overall satisfaction with social support from friends and 
families, ranging from 0 (very dissatisfied) to 3 (Very satisfied). For substance use, there 
was a frequency question about binge drinking, asking how often participants drank 5 or 
more drinks of alcohol in the past month, ranging from never (0), to daily (6), a series of 
yes/no questions for various substances (e.g., cocaine, heroin, marijuana), followed by the 
frequency question for the substance used most. Lastly, there were questions about sexual 
behaviors in the past week, which yielded a variable indicating whether participants reported 
any condomless sex acts in the past week.
Viral Suppression—HIV-1 plasma viral load was collected quarterly, and viral 
suppression was defined as HIV-1 plasma viral load <400 copies/mL.
Safren et al. Page 4














Logistic (allowing for odds ratios) and linear regression (for continuous measures, with an 
unstandardized beta as the parameter estimate) models using generalized estimating 
equation (GEE) for repeated measurements were first fit to examine the associations 
between adherence measured by pill count and self-report with psychosocial and 
demographic predictors, respectively. In model building, all variables associated with the 
outcome with p<0.1 from the univariate regression model were included in later 
multivariable regression models. Similarly, logistic regression models were fit to examine 
the association between the two indicators of adherence (pill count and self-report) on viral 
suppression status (suppressed vs detectable) including the psychosocial and demographic 
predictors as covariates. All analyses were conducted using SAS version 9.2 (SAS Inc., 
Cary, NC).
RESULTS
Demographic variables for the sample are reported in the primary outcome paper for HPTN 
0521 and are included in the on-line Supplemental Appendix. Table 1 presents descriptive 
baseline data on the psychosocial and demographic data for the present sample. General 
health perception and mental health scores were in expected ranges, and most participants 
reported that they were either somewhat or very satisfied with social support. A small 
minority reported substance use, though almost 20% reported binge drinking. Only 4.2% of 
the sample reported less than 100% condom use during sex.
Levels of adherence and reasons for non-adherence
According to pill count, in the first month following ART initiation, 82.2% of participants 
were “adherent” (defined by 95% or greater levels), and 83.2% of participants were adherent 
one year after ART initiation. With respect to self-report items for how often they missed 
doses after ART initiation, 88.8% reported less than perfect adherence in the first month, 
and 84.2% at one year. In the first month the most frequent (more than 5%) reasons for non-
adherence were: forgot (40.4%), traveling away from home (19.3%), wanted to avoid side 
effects (17.0%), busy doing other things (9.4%), other illness or health problems got in the 
way (8.2%), and ran out of pills (6.4%). At one year, the most frequent reasons given for 
non-adherence were: forgot (45.1%), busy doing other things (20.7), traveling away from 
home (22.6%), and ran out of pills (14%).
Longitudinal models of adherence
Pill count adherence—Tables 2 and 3 present univariate and multivariable logistic 
regression analyses of psychosocial and demographic predictors of pill count adherence, 
inclusive of corresponding odds ratios, confidence intervals, and significance levels. 
According to the estimates in both the univariate and multivariable analyses, having a higher 
mental health score was the only statistically significant psychosocial predictor associated 
with greater adherence as measured by pill count. Geographic region (specifically, Asia and 
Africa versus America) were also associated with adherence, with both groups having higher 
pill count adherence than America. In the univariate analyses, in addition to higher mental 
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health scores, higher general health perceptions and lower levels of unprotected sex were 
associated with greater adherence by pill count.
Self report (PCA) adherence score—Tables 2 and 3 also present univariate and 
multivariable linear regression analyses of psychosocial predictors of adherence measured 
by the self-report PCA scores,,with corresponding unstandardized beta regression coefficient 
estimates, confidence intervals, and significance levels. Similar to the adherence by pill-
count, in both the univariate and the multivariable analyses, having a higher mental health 
score was statistically significantly associated with better adherence. However, in the 
analysis by geographic region, participants from Asia had lower self-reported adherence. 
Additionally, older age was associated with higher adherence in univariate analysis, but only 
marginally significant (p=.06) in multivariable analysis, Better social support (somewhat 
satisfied versus very dissatisfied) was associated with better adherence in univariate analysis 
only.
Predictors of viral suppression (Table 4)
Both univariate and multivariable analyses showed consistent significant associations 
between the self-report PCA medication adherence score and viral suppression. In the 
multivariable analysis of pill count adherence, those categorized as being 95-100% adherent 
were 1.42 times more likely to be virally suppressed; analysis of the self-report PCA 
adherence score showed each unit increase in the PCA resulting in a 1.20 fold increased 
likelihood of being virally suppressed.
DISCUSSION
ART that suppresses HIV-1 replication reduces transmission of HIV-1 to a sexual partner; 
however, this benefit requires strict adherence to treatment. Treatment for prevention 
purposes generally requires initiating ART when patients are healthier and therefore at 
higher CD4 counts. One study20 compared 60 individuals in Uganda with CD4<250 cells to 
those >=250 cells and found greater number of treatment interruptions and more 
uncontrolled virus in those in the higher baseline CD4 category. No studies have examined 
adherence to ART when the stated purpose of the ART was specifically to test whether it 
would reduce transmission of HIV-1 to a sexual partner.
In the present analysis, we noted higher levels of adherence to ART than typically observed 
in the context of ART for treatment.21 In addition, such adherence in the infected person is 
greater than reported in an observational study of couples in Zambia.22 The high level of 
adherence in this report may have reflected the intense management in the conduct of the 
HPTN 052 study,1,9 the benefit of couples counseling,23 feedback about viral load 
suppression, or altruism related to prevention of transmission of HIV (a potential benefit 
communicated during the informed consent process). Additionally, counselors used an 
evidenced-based cognitive-behavioral counseling intervention (Life-Steps)10,24 as the basis 
of their adherence counseling training, and utilized checklists and visit documentation to 
maximize the actual delivery of this counseling approach in these settings.
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We found that the only psychosocial variable that predicted adherence in the multivariable 
models was the mental health score on the quality of life assessment. While the association 
of mental health to adherence is consistent with meta-analytic work in individuals with 
HIV-1 showing an association of depression to non-adherence,25 the lack of associations of 
variables such as substance use26–28 and social support,29 differs from what has been 
reported in studies of adherence in patients prescribed ART for treatment.
Our HIV-1 serodiscordant couples were in relatively stable relationships, located in 
resource-limited countries where initiation of ART was recommended at lower CD4 cell 
counts than what was dictated by the study, and who were volunteering for a HIV 
prevention trial where provision of care might be greater than what would otherwise be 
received in the local setting. Accordingly, participants electing to take medications for 
prevention purposes, and/or for purposes of being in a prevention trial may have higher 
motivation for health behaviors in general. Hence, as seen in the present study, the strength 
of the association of some of the typical psychosocial variables to health behavior may be 
attenuated when the need for treatment is also not as strong.
Nevertheless, higher mental health scores remained independently associated with better 
adherence. A treatment study that complemented HPTN 052 and was conducted at the same 
sites, ACTG5175,30 found that illicit drug use and general health perceptions but not mental 
health scores were variables associated with adherence in longitudinal multivariable 
models.15 These results suggest that there may be different psychosocial variables predicting 
adherence when attempting to maximize ART for prevention rather than ART for treatment.
There are several limitations to this analysis. First, self-report and pill-count adherence are 
not as objective as other indicators such as medication event monitoring systems (MEMs), 
other electronically monitored adherence devices, unannounced pill counts, or blood ART 
levels. However, the association of viral load to both pill count and self-report PCA 
adherence scores shows that these can be useful indicators of adherence.31 Second, this 
analysis mainly examined main effects, and not interactions because of the wide number of 
potential variables possible for interactions such as study site, HIV risk group, gender, and 
country. Third, although participants enrolled in the study as a prevention trial, it is possible 
that some participants’ motivation to join was as a vehicle to gaining ART as treatment for 
themselves. Hence, although at the time the study began initiating ART was not considered 
necessarily beneficial to the patient, this could have affected the motivations to take ART 
and be adherent to ART.
The results of this analysis demonstrate a very high degree of adherence to ART, which 
correlates well with the durable suppression of viremia observed.1,9 It seems likely that high 
adherence can be expected in many groups of couples given the fact that ART dramatically 
suppressed HIV transmission in 10/12 observational studies.32 Adherence to treatment is 
likely optimized when evidence based counseling is an ongoing part of provision of 
ART,33,34 when couples are counseled together, when the prevention benefit to the sexual 
partner is made clear, and when feedback about viral suppression is provided. These data 
suggest the potential utility of implementing these approaches in clinical settings.
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